DepoCyte

RSS

Withdrawn

This medicine's authorisation has been withdrawn

cytarabine
MedicineHumanWithdrawn

Danish is available via eTranslation, the European Commission's machine translation service.

Translate to Danish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 10 July 2018, the European Commission withdrew the marketing authorisation for DepoCyte (cytarabine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Pacira Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

DepoCyte was granted marketing authorisation in the EU on 11 July 2001 for the intrathecal treatment of lymphomatous meningitis. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2011. 

The European Public Assessment Report (EPAR) for DepoCyte is updated to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (661.62 KB - PDF)

Vis

español (ES) (569.14 KB - PDF)

Vis

čeština (CS) (632.39 KB - PDF)

Vis

dansk (DA) (569.13 KB - PDF)

Vis

Deutsch (DE) (714.1 KB - PDF)

Vis

eesti (ET) (568.03 KB - PDF)

Vis

ελληνικά (EL) (1.25 MB - PDF)

Vis

français (FR) (569.55 KB - PDF)

Vis

italiano (IT) (572.16 KB - PDF)

Vis

latviešu (LV) (637.75 KB - PDF)

Vis

lietuvių (LT) (593.61 KB - PDF)

Vis

magyar (HU) (627.27 KB - PDF)

Vis

Malti (MT) (571.84 KB - PDF)

Vis

Nederlands (NL) (568.96 KB - PDF)

Vis

polski (PL) (632.99 KB - PDF)

Vis

português (PT) (570.42 KB - PDF)

Vis

română (RO) (592.76 KB - PDF)

Vis

slovenčina (SK) (630.99 KB - PDF)

Vis

slovenščina (SL) (626.68 KB - PDF)

Vis

suomi (FI) (568.87 KB - PDF)

Vis

svenska (SV) (568.38 KB - PDF)

Vis

Product information

български (BG) (1.36 MB - PDF)

Vis

español (ES) (798.17 KB - PDF)

Vis

čeština (CS) (1.18 MB - PDF)

Vis

dansk (DA) (840.85 KB - PDF)

Vis

Deutsch (DE) (1.1 MB - PDF)

Vis

eesti (ET) (770.12 KB - PDF)

Vis

ελληνικά (EL) (2.4 MB - PDF)

Vis

français (FR) (786.49 KB - PDF)

Vis

hrvatski (HR) (322.7 KB - PDF)

Vis

italiano (IT) (780.81 KB - PDF)

Vis

latviešu (LV) (1.15 MB - PDF)

Vis

lietuvių (LT) (800.85 KB - PDF)

Vis

magyar (HU) (1.14 MB - PDF)

Vis

Malti (MT) (1.13 MB - PDF)

Vis

Nederlands (NL) (776.99 KB - PDF)

Vis

polski (PL) (1.13 MB - PDF)

Vis

português (PT) (778.53 KB - PDF)

Vis

română (RO) (897.66 KB - PDF)

Vis

slovenčina (SK) (1.11 MB - PDF)

Vis

suomi (FI) (771.39 KB - PDF)

Vis

svenska (SV) (765.06 KB - PDF)

Vis

Íslenska (IS) (279.42 KB - PDF)

Vis

norsk (NO) (284.34 KB - PDF)

Vis
Latest procedure affecting product information:N/0059
26/06/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (538.83 KB - PDF)

Vis

español (ES) (512.35 KB - PDF)

Vis

čeština (CS) (531.7 KB - PDF)

Vis

dansk (DA) (506.59 KB - PDF)

Vis

eesti (ET) (496.5 KB - PDF)

Vis

ελληνικά (EL) (520.27 KB - PDF)

Vis

français (FR) (505.96 KB - PDF)

Vis

italiano (IT) (502.84 KB - PDF)

Vis

latviešu (LV) (531.14 KB - PDF)

Vis

lietuvių (LT) (517.85 KB - PDF)

Vis

magyar (HU) (522.39 KB - PDF)

Vis

Malti (MT) (533.64 KB - PDF)

Vis

Nederlands (NL) (505.52 KB - PDF)

Vis

polski (PL) (531.52 KB - PDF)

Vis

português (PT) (512.51 KB - PDF)

Vis

română (RO) (518.92 KB - PDF)

Vis

slovenčina (SK) (530.76 KB - PDF)

Vis

slovenščina (SL) (520.2 KB - PDF)

Vis

suomi (FI) (502.61 KB - PDF)

Vis

svenska (SV) (513.13 KB - PDF)

Vis

Product details

Name of medicine
DepoCyte
Active substance
cytarabine
International non-proprietary name (INN) or common name
cytarabine
Therapeutic area (MeSH)
Meningeal Neoplasms
Anatomical therapeutic chemical (ATC) code
L01BC01

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.

Authorisation details

EMA product number
EMEA/H/C/000317
Marketing authorisation holder
Pacira Limited

3 Glory Park Avenue
Wooburn Green
High Wycombe
Buckinghamshire
HP10 0DF
United Kingdom

Opinion adopted
10/07/2018
Marketing authorisation issued
11/07/2001
Revision
15

Assessment history

This page was last updated on

Share this page